Biotech · Private company
Convergent Therapeutics
Track this companyFree. Adds Convergent Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- 45 kBq/kg Ac-225 rosopatamab tetraxetanPhase 2 · PSMA PET-Positive Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetanPhase 2 · PSMA PET-Positive Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- 60 kBq/kg Ac-225 rosopatamab tetraxetanPhase 2 · PSMA PET-Positive Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- In-111 rosopatamab tetraxetanPhase 2 · PSMA PET-Positive Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- Single dose 22 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetanPhase 2 · PSMA PET-Positive Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- Single dose 34 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetanPhase 2 · PSMA PET-Positive Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)PHASE2 · RECRUITING · started Aug 6, 2024ClinicalTrials.gov NCT06549465 · fetched Nov 12, 2026